Tilray Brands, Inc. Operating Lease, Liability, Noncurrent
Tilray Brands, Inc. (TLRY) had Operating Lease, Liability, Noncurrent of $38.47 million as of 2026-05-31, per its 10-K filed 2026-07-28.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-07-28
- 2026-05-31: Operating Lease, Liability, Noncurrent $38.47M.
- 2026-02-28: Operating Lease, Liability, Noncurrent $17.06M.
- 2025-11-30: Operating Lease, Liability, Noncurrent $18.14M.
- 2025-08-31: Operating Lease, Liability, Noncurrent $19.38M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-05-31 | $38.47M 10-K · filed 2026-07-28 |
| 2026-02-28 | $17.06M 10-Q · filed 2026-04-01 |
| 2025-11-30 | $18.14M 10-Q · filed 2026-01-08 |
| 2025-08-31 | $19.38M 10-Q · filed 2025-10-09 |
| 2025-05-31 | $20.63M 10-K · filed 2026-07-28 |
| 2025-02-28 | $15.57M 10-Q · filed 2025-04-08 |
| 2024-11-30 | $17.00M 10-Q · filed 2025-01-10 |
| 2024-08-31 | $16.92M 10-Q · filed 2024-10-10 |
| 2024-05-31 | $16.47M 10-K · filed 2025-07-29 |
| 2023-05-31 | $7.94M 10-K · filed 2024-07-30 |
| 2022-05-31 | $11.33M 10-K · filed 2022-07-28 |
| 2021-05-31 | $18.46M 10-K · filed 2022-07-28 |
| 2020-12-31 | $15.35M 10-K · filed 2021-02-19 |
| 2020-05-31 | $4.23M 10-K · filed 2021-07-28 |
| 2019-12-31 | $15.26M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |